1388 (1388) Fair Value & Analysis

Consumer Cyclical · Market cap HK$127M

1 1388 1388 · HK

PriceHK$0.3000

Fair ValueHK$0.2026

Upside-32.5%

Quality47/100

Evidence: Low Range HK$0.1507 – HK$0.3023

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −6.3% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.2800 – HK$0.4750 · fair‑value band HK$0.1507 – HK$0.3023 · the HK$0.3000 price screens above the HK$0.2026 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1388 (1388) currently trades at HK$0.3000, while our model-based Fair Value estimate is HK$0.2026 — implying the stock looks roughly 32.5% overvalued today. We read business quality at 47/100 (below-average quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 1388 generated revenue of HK$1.2B at a net margin of -21.6%. Revenue grew 8.5% year over year. It earns a return on equity of -15.5%. Net debt stands at HK$287M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.2B

Revenue growth (YoY) +8.5%

Net margin -21.6%

Return on equity -15.5%

Free cash flow −HK$37.2M FY2025

Operating margin -20.7%

More key figures

EPS (TTM) HK$-0.1400

EPS growth (YoY) +389%

Net debt HK$287M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1388 reported revenue of HK$1.2B in FY2025 versus HK$1.7B in FY2021, a compound −8.3%/yr. Reported net income was −HK$253M in FY2025.

Revenue −8.3%/yr

FY21 HK$1.7B

FY22 HK$1.3B

FY23 HK$1.3B

FY24 HK$1.2B

FY25 HK$1.2B

Net income

FY21 −HK$27.5M

FY22 −HK$51.2M

FY23 −HK$72.2M

FY24 −HK$373M

FY25 −HK$253M

Is 1388 fairly valued? → Check now

Similar stocks

6 more Apparel Manufacturing stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
H & M Hennes & Mauritz AB HMB	kr 164.90	kr 165.47	+0%
Ralph Lauren Corporation RL	$376.43	$423.69	+13%
Moncler S.p.A MONC	€50.90	€50.69	-0%
Gildan Activewear Inc GIL	$57.04	$34.84	-39%
LPP SA LPP	21,720 PLN	18,670 PLN	-14%
Levi Strauss & Co LEVI	$23.61	$16.83	-29%

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1388 (1388) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.2026 versus a price of HK$0.3000 — about −32% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1388?

Our model-based fair value for 1388 is HK$0.2026 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.3000.

What is the quality score of 1388?

1388 has a Quality Score of 47/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1388 (1388)?

1388 reported trailing-twelve-month revenue of about HK$1.2B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1388?

The net profit margin of 1388 is about -21.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.